» Articles » PMID: 31610125

Tc-, Y-, and Lu-Labeled Iron Oxide Nanoflowers Designed for Potential Use in Dual Magnetic Hyperthermia/Radionuclide Cancer Therapy and Diagnosis

Overview
Date 2019 Oct 15
PMID 31610125
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Development of a complex based on iron oxide nanoparticles (IONPs) for diagnosis and dual magnetic hyperthermia/radionuclide cancer therapy accomplishing high yields of radiolabeling and great magnetic heat induction is still a challenge. We report here the synthesis of citric acid, poly(acrylic acid) (PAA) and poly(ethylene glycol) coated IONPs and their labeling with three radionuclides, namely, technetium (Tc), yttrium (Y), and lutetium (Lu), aiming at potential use in cancer diagnosis and therapy. Polyol-synthesized IONPs are a flowerlike structure with 13.5 nm spherically shaped cores and 24.8 nm diameter. PAA-coated nanoparticles (PAA@IONP) showed the best characteristics such as easy radiolabeling with very high yields (>97.5%) with all three radionuclides, and excellent in vitro stabilities with less than 10% of radionuclides detaching after 24 h. Heating ability of PAA@IONP in an alternating external magnetic field showed intrinsic loss power value of 7.3 nH m/kg, which is one of higher reported values. Additionally, PAA@IONP itself presented no significant cytotoxicity to the CT-26 cancer cells, reaching IC50 at 60 μg/mL. However, under the external magnetic field, they show hyperthermia-mediated cells killing, which correlated with the magnetic field strength and time of exposure. Since PAA@IONP are easy to prepare, biocompatible, and with excellent magnetic heat induction, these nanoparticles radiolabeled with high-energy beta emitters Y and Lu have valuable potential as agent for dual magnetic hyperthermia/radionuclide therapy, while radiolabeled with Tc could be used in diagnostic imaging.

Citing Articles

Approaches to Nanoparticle Labeling: A Review of Fluorescent, Radiological, and Metallic Techniques.

Chen H, Hu Q, Li W, Cai X, Mao L, Li R Environ Health (Wash). 2024; 1(2):75-89.

PMID: 39473584 PMC: 11504608. DOI: 10.1021/envhealth.3c00034.


Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape.

Reilly R, Georgiou C, Brown M, Cai Z EJNMMI Radiopharm Chem. 2024; 9(1):37.

PMID: 38703297 PMC: 11069497. DOI: 10.1186/s41181-024-00266-y.


Methods for Radiolabeling Nanoparticles (Part 3): Therapeutic Use.

Bentivoglio V, Nayak P, Varani M, Lauri C, Signore A Biomolecules. 2023; 13(8).

PMID: 37627307 PMC: 10452659. DOI: 10.3390/biom13081241.


Emulsion Technology in Nuclear Medicine: Targeted Radionuclide Therapies, Radiosensitizers, and Imaging Agents.

Winuprasith T, Koirala P, McClements D, Khomein P Int J Nanomedicine. 2023; 18:4449-4470.

PMID: 37555189 PMC: 10406121. DOI: 10.2147/IJN.S416737.


Synthesis, Characterization, and Therapeutic Efficacy of Lu-DMSA@SPIONs in Nanobrachytherapy of Solid Tumors.

Stankovic D, Radovic M, Stankovic A, Mirkovic M, Vukadinovic A, Mijovic M Pharmaceutics. 2023; 15(7).

PMID: 37514129 PMC: 10384743. DOI: 10.3390/pharmaceutics15071943.